Tandem has announced their newest pump, the t:slim X2. This update to the t:slim Insulin Pump has improved bluetooth capabilities and works with the Tandem Device Updater for remote software updates from a personal computer. The addition of the bluetooth radio will allow future devices and applications to "talk" directly to the pump. The Tandem Device Updater allows users to update the software on their pumps without purchasing a replacement unit. It has the potential to enable users to add new features without worrying about normal insurance pump replacement cycles.
Minimed received FDA approval for its 670G system in September 2016. Expected to ship in Spring of 2017, the 670G automatically adjusts the delivery of your basal insulin based on readings from Minimed's new CGM, the Guardian Sensor 3 and the Guardian Link 3 transmitter. The sensors are said to have a 7-day life span while being continuously monitored by their new diagnostic technology that monitors how the sensor is doing. This is currently the only sensor approved to drive the amount of insulin delivered by a pump.
A provocative article on the front page of the Sunday’s New York Times (April 6, 2014) took on the high cost of diabetes care and investigated several areas of medical advancements as well as outrageous pricing. The article asks startling questions such as: Are your favorite diabetes drugs and devices relevant to your treatment?
The Asante Snap (No Longer Available) began to ship in April of 2013, two years after receiving FDA approval. The Snap is being rolled out by region, starting in the Northeast US, with gradual availability to other regions. This allows Asante to build up their sales and service network (Similar to Insulet’s rollout of the Omnipod). Asante has focused on ease of pump use and highlights how easy it is to use the Snap pump and change out the cartridge, among other things.
The FDA approved the Medtronic MiniMed 530G insulin pump with its display of the Enlite continuous glucose monitor in September, 2013. The 530G is the first system in the United States that can automatically stop insulin delivery if the CGM's glucose value falls to a preset level (60-90 mg/dl) AND the wearer doesn't respond to the Threshold Suspend Alarm. This functionality puts the device in the newly created OZO: Artificial Pancreas Device Classification created by the U.S. Food and Drug Administration.
The Animas Vibe is an insulin pump with a built in Dexcom Continuous Glucose Monitor. Although there is a pump-only version of the Vibe available, the combination of the pump and monitor are what makes the Vibe stand out. The Vibe, alone, is basically the Animas 2020 pump platform from a few years ago.
The Vibe has been available in the UK since 2011. Johnson & Johnson finally submitted the Animas Vibe to the FDA in April of 2013.
When choosing a pump, take the time you need to make a good choice. You will depend on this pump for 4 to 5 years, so discuss different pumps and pump options with your doctor and health care team to select the features that will be most helpful. Be sure to take a look at our Pump Comparison Page to help with your pump choice.